
Transcat, Inc. (NASDAQ:TRNS – Free Report) – Investment analysts at Northland Securities decreased their Q2 2027 earnings per share estimates for shares of Transcat in a research report issued on Wednesday, August 5th. Northland Securities analyst T. Jackson now forecasts that the scientific and technical instruments company will post earnings of $0.41 per share for the quarter, down from their prior estimate of $0.45. Northland Securities has a “Market Perform” rating and a $95.00 price target on the stock. The consensus estimate for Transcat’s current full-year earnings is $1.71 per share. Northland Securities also issued estimates for Transcat’s Q4 2027 earnings at $0.60 EPS, FY2027 earnings at $1.71 EPS and FY2031 earnings at $3.53 EPS.
Transcat (NASDAQ:TRNS – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The scientific and technical instruments company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.13. The firm had revenue of $92.95 million for the quarter, compared to analysts’ expectations of $86.55 million. Transcat had a net margin of 0.99% and a return on equity of 5.59%.
Get Our Latest Stock Report on Transcat
Transcat Stock Up 2.0%
Shares of TRNS stock opened at $93.75 on Thursday. The company’s fifty day simple moving average is $89.11 and its two-hundred day simple moving average is $79.29. Transcat has a 52 week low of $50.23 and a 52 week high of $95.22. The stock has a market cap of $877.50 million, a P/E ratio of 253.38 and a beta of 0.68. The company has a quick ratio of 1.99, a current ratio of 2.33 and a debt-to-equity ratio of 0.33.
Institutional Investors Weigh In On Transcat
Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Transcat by 0.4% during the third quarter. Vanguard Group Inc. now owns 530,771 shares of the scientific and technical instruments company’s stock worth $38,852,000 after acquiring an additional 2,041 shares during the period. Royce & Associates LP boosted its holdings in shares of Transcat by 15.3% in the fourth quarter. Royce & Associates LP now owns 390,546 shares of the scientific and technical instruments company’s stock valued at $22,156,000 after purchasing an additional 51,774 shares during the period. Dimensional Fund Advisors LP grew its stake in Transcat by 3.7% in the first quarter. Dimensional Fund Advisors LP now owns 262,033 shares of the scientific and technical instruments company’s stock worth $19,244,000 after purchasing an additional 9,266 shares in the last quarter. Wellington Management Group LLP grew its stake in Transcat by 677.7% in the fourth quarter. Wellington Management Group LLP now owns 248,539 shares of the scientific and technical instruments company’s stock worth $14,100,000 after purchasing an additional 216,579 shares in the last quarter. Finally, Bamco Inc. NY increased its holdings in Transcat by 6.2% during the 4th quarter. Bamco Inc. NY now owns 203,477 shares of the scientific and technical instruments company’s stock worth $11,543,000 after purchasing an additional 11,911 shares during the period. 98.34% of the stock is owned by hedge funds and other institutional investors.
Transcat News Roundup
Here are the key news stories impacting Transcat this week:
- Positive Sentiment: Transcat’s latest quarter exceeded expectations on an adjusted basis, with EPS of $0.51 versus the $0.38 consensus estimate and revenue of $92.95 million versus expectations of $86.55 million. Revenue increased 21.6% year over year to approximately $92.9 million, supported by continued demand for measurement, calibration and technical services. Transcat Q1 Earnings and Revenues Top Estimates
- Positive Sentiment: Management is targeting high-single-digit organic growth in its Service segment and is emphasizing operational excellence, providing a potential path to sustain top-line momentum and improve execution. Transcat Targets High-Single-Digit Service Organic Growth
- Neutral Sentiment: Operating cash flow rose sharply to $8.8 million, up 143.4% year over year, but the company’s balance sheet also showed higher liabilities. Institutional interest was mixed, with 78 investors adding shares and 63 reducing positions in the latest reporting period.
- Negative Sentiment: Despite strong sales, profitability deteriorated: operating profit declined 30.3% and net income fell 59.2% year over year in the reported figures. The divergence between revenue growth and margins may be contributing to analyst caution. Transcat Q1 2027 Earnings Analysis
- Negative Sentiment: Northland Securities reduced its EPS forecasts for Q2 2027 to $0.41 from $0.45, FY2027 to $1.71 from $1.86, Q4 2027 to $0.60 from $0.62, and FY2031 to $3.53 from $3.88. The firm maintained its “Market Perform” rating and $95 target, reinforcing concerns about slower earnings growth and margin pressure.
Transcat Company Profile
Transcat, Inc (NASDAQ: TRNS) is a leading provider of calibration, laboratory, and metrology services in North America. Founded in 1964 and headquartered in Ronkonkoma, New York, the company specializes in ensuring the accuracy and compliance of measurement instruments across a wide range of industries. Transcat operates a network of ISO/IEC 17025–accredited laboratories and offers on-site field calibration, instrument repair, and preventive maintenance services.
In addition to its calibration services, Transcat distributes precision instrumentation and related software solutions from top manufacturers.
See Also
- Five stocks we like better than Transcat
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.
